Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

165.18 +2.51 (+1.54%)
Streaming Delayed Price Updated: 11:19 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
42 43 Next >
News headline image
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
News headline image
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
News headline image
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
News headline image
Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations ↗
Via Stocktwits
Topics Cannabis
News headline image
Is Novartis Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases. 
Via Benzinga
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Solid Value Pick in Pharmaceuticals ↗
NOVARTIS AG (NYSE:NVS) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector. 
Via Chartmill
News headline image
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company ↗
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
News headline image
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder ↗
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress. 
Via Benzinga
News headline image
2 Dividend Growth Stocks to Buy and Hold Forever ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position ↗
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.” 
Via Stocktwits
Topics ETFs
News headline image
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 ↗
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
The Smartest Vanguard ETF to Buy With $500 Right Now ↗
Via The Motley Fool
Topics ETFs
News headline image
Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years ↗
This company stands to benefit from the advances in artificial intelligence more than any other business. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks ↗
IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors. 
Via Benzinga
Topics ETFs
News headline image
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
News headline image
Here's My Favorite High-Dividend ETF to Buy Right Now ↗
Via The Motley Fool
Topics ETFs
News headline image
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting. 
Via Benzinga
News headline image
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
News headline image
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion ↗
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion. 
Via Benzinga
News headline image
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
News headline image
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline ↗
Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership. 
Via Benzinga
Topics Earnings
News headline image
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million ↗
Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025. 
Via Benzinga
News headline image
AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition ↗
Edgewater noted that the mobile gaming macro environment appears to be decelerating gradually, while competition from both Meta and Alphabet is intensifying. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis ↗
According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million. 
Via Stocktwits
News headline image
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance ↗
Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales. 
Via Benzinga
Topics Earnings
News headline image
Novartis Creeps Toward A Breakout On Its Beat-And-Raise ↗
Shares are consolidating and are now trading above their 50-day and 200-day lines. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.